Ranbaxy, Cipher Agree To Expand Acne Drug License To Brazil
This article was originally published in PharmAsia News
Executive Summary
Ranbaxy Laboratories and Cipher Pharmaceuticals have signed an agreement extending their distribution and marketing contract for the Canada drug maker's Absorica (isotretinoin) acne treatment in Brazil.